Aug 07, 2025 • Benzinga
SOMEWHAT-BULLISH
These Analysts Revise Their Forecasts On Viridian Therapeutics Following Q2 Results - Viridian Therapeutics ( NASDAQ:VRDN )
Viridian Therapeutics, Inc. VRDN reported upbeat results for the second quarter on Wednesday. The company posted quarterly losses of $ ( 1.00 ) per share which beat the analyst consensus estimate of $ ( 1.02 ) per share.
Aug 06, 2025 • Motley Fool
SOMEWHAT-BULLISH
Viridian ( VRDN ) Q2 Net Loss Widens 55%
Viridian Therapeutics ( NASDAQ:VRDN ) , a biotechnology company focused on therapies for autoimmune diseases including thyroid eye disease ( TED ) , released its second quarter 2025 results on August 6, 2025. The report highlighted major clinical progress with its lead TED candidate, veligrotug, ...
Aug 06, 2025 • Zacks Commentary
NEUTRAL
Viridian Therapeutics, Inc. ( VRDN ) Reports Q2 Loss, Misses Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 0.00% and -48.63%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
May 06, 2025 • Zacks Commentary
NEUTRAL
Viridian Therapeutics, Inc. ( VRDN ) Reports Q1 Loss, Lags Revenue Estimates
Viridian Therapeutics (VRDN) delivered earnings and revenue surprises of 8.42% and 55.83%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Apr 21, 2025 • Benzinga
SOMEWHAT-BULLISH
Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders - Zevra Therapeutics ( NASDAQ:ZVRA )
Highlights 54.8% Total Stockholder Return Under Refreshed Board and Management Team Zevra Continues Growth Trajectory into a Global Commercial Rare Disease Company with Consistent Execution, New Product Launches, and Significant Financial Flexibility to Execute Strategic Plan
Apr 21, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Zevra Files Definitive Proxy Statement and Mails Letter to Stockholders
Highlights 54.8% Total Stockholder Return Under Refreshed Board and Management Team ...